Hereditary colorectal cancer

New England Journal of Medicine

Volumn 348, Issue 10, 2003, Pages 919-932

  Lynch, Henry T ^a   De la Chapelle, Albert ^b  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; MICROSATELLITE DNA; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN MLH1; PROTEIN MSH2; SULINDAC;

ADENOMATOUS POLYP; AUTOSOMAL DOMINANT DISORDER; CANCER EPIDEMIOLOGY; CANCER LOCALIZATION; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; CARCINOGENESIS; CHEMOPROPHYLAXIS; CLINICAL FEATURE; CLINICAL TRIAL; COLON ADENOMA; COLORECTAL CANCER; CPG ISLAND; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE COURSE; ENDOMETRIUM CANCER; ENDOSCOPIC POLYPECTOMY; ENDOSCOPY; FAMILIAL CANCER; FAMILY; FAMILY HISTORY; GENE MUTATION; GENETIC ANALYSIS; GENETIC COUNSELING; GENETIC POLYMORPHISM; GERM LINE; HIGH RISK POPULATION; HUMAN; JAPAN; KOREA; METHYLATION; MISMATCH REPAIR; MISSENSE MUTATION; ONSET AGE; PATHOGENICITY; PEDIGREE; PENETRANCE; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SOMATIC MUTATION; TREATMENT INDICATION; TUMOR LOCALIZATION;

ADENOMATOUS POLYPOSIS COLI; COLORECTAL NEOPLASMS; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; FEMALE; GENETIC SCREENING; GERM-LINE MUTATION; HUMANS; MALE; MICROSATELLITE REPEATS; MUTATION; PEDIGREE;

EID: 0037422027     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMra012242     Document Type: Review

References (102)

1. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002;52:23-47. [Errata, CA Cancer J Clin 2002;52:119, 181-2.]
2. Polednak AP. Do physicians discuss genetic testing with family-history-positive breast cancer patients? Conn Med 1998;62: 3-7.
3. Cho MK, Sankar P, Wolpe PR, Godmilow L. Commercialization of BRCA1/2 testing: practitioner awareness and use of a new genetic test. Am J Med Genet 1999;83:157-63.
4. Giardiello FM, Brensinger JD, Petersen GM, et al. The use and interpretation of commercial APC gene testing for familial adenomatous polyposis. N Engl J Med 1997; 336:823-7.
5. Vogelstein B, Kinzler KW, eds. The genetic basis of human cancer. New York: McGraw-Hill, 1998.
6. Eng C, Hampel H, de la Chapelle A. Genetic testing for cancer predisposition. Annu Rev Med 2001;52:371-400. [Erratum, Annu Rev Med 2002;53:xi.]
7. Lynch HT, de la Chapelle A. Genetic susceptibility to nonpolyposis colorectal cancer. J Med Genet 1999;36:801-18.
8. Lynch HT. Family information service and hereditary cancer. Cancer 2001;91:625-8.
9. Aktan-Collan K, Mecklin JP, Jarvinen HJ, et al. Predictive genetic testing for hereditary nonpolyposis colorectal cancer: uptake and long-term satisfaction. Int J Cancer 2000;89:44-50.
10. Lynch HT, Smyrk T, McGinn T, et al. Attenuated familial adenomatous polyposis (AFAP): a phenotypically and genotypically distinctive variant of FAP. Cancer 1995;76:2427-33.
11. Lynch HT, Lynch JF, Casey MJ, Bewtra C, Narod SA. Genetics of gynecological cancer. In: Hoskins WJ, Perez CA, Young RC, eds. Principles and practice of gynecologic oncology. 3rd ed. Philadelphia: Lippincott Williams & Wilkins, 2000:29-53.
12. Watson P, Lynch HT. The tumor spectrum in HNPCC. Anticancer Res 1994;14: 1635-9.
13. Watson P, Lin KM, Rodriguez-Bigas MA, et al. Colorectal carcinoma survival among hereditary nonpolyposis colorectal carcinoma family members. Cancer 1998;83:259-66.
14. Sankila R, Aaltonen LA, Jarvinen HJ, Mecklin J-P. Better survival rates in patients with MLH1-associated hereditary colorectal cancer. Gastroenterology 1996;110:682-7.
15. Gryfe R, Kim H, Hsieh ETK, et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 2000;342:69-77.
16. Branch P, Bicknell DC, Rowan A, Bodmer WF, Karran P. Immune surveillance in colorectal carcinoma. Nat Genet 1995;9: 231-2.
17. Shashidharan M, Smyrk T, Lin KM, et al. Histologic comparison of hereditary nonpolyposis colorectal cancer associated with MSH2 and MLH1 and colorectal cancer from the general population. Dis Colon Rectum 1999;42:722-6.
18. Boman BM, Fry RD, Curran W, et al. Unique immunohistochemical features of MSI-classified tumors from HNPCC patients. Prog Proc Am Soc Clin Oncol 1999;19:236a. abstract.
19. Aaltonen LA, Peltomaki P, Leach FS, et al. Clues to the pathogenesis of familial colorectal cancer. Science 1993;260:812-6.
20. Peltomaki P, Lothe RA, Aaltonen LA, et al. Microsatellite instability is associated with tumors that characterize the hereditary nonpolyposis colorectal carcinoma syndrome. Cancer Res 1993;53:5853-5.
21. Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998;58:5248-57.
22. Aaltonen LA, Salovaara R, Kristo P, et al. Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med 1998;338:1481-7.
23. Salovaara R, Loukola A, Kristo P, et al. Population-based molecular detection of hereditary nonpolyposis colorectal cancer. J Clin Oncol 2000;18:2193-200. [Erratum, J Clin Oncol 2000;18:3456.]
24. Lothe RA, Peltomaki P, Meling GI, et al. Genomic instability in colorectal cancer: relationship to clinicopathological variables and family history. Cancer Res 1993;53:5849-52.
25. Thibodeau SN, French AJ, Cunningham JM, et al. Microsatellite instability in colorectal cancer: different mutator phenotypes and the principal involvement of hMLH1. Cancer Res 1998;58:1713-8.
26. Zhou X-P, Hoang J-M, Li Y-J, et al. Determination of the replication error phenotype in human tumors without the requirement for matching normal DNA by analysis of mononucleotide repeat microsatellites. Genes Chromosomes Cancer 1998;21:101-7.
27. de la Chapelle A. Testing tumors for microsatellite instability. Eur J Hum Genet 1999;7:407-8.
28. Nyström-Lahti M, Kristo P, Nicolaides NC, et al. Founding mutations and Alumediated recombination in hereditary colon cancer. Nat Med 1995;1:1203-6.
29. Aaltonen LA, Peltomaki P, Mecklin JP, et al. Replication errors in benign and malignant tumors from hereditary nonpolyposis colorectal cancer patients. Cancer Res 1994; 54:1645-8.
30. Miyaki M, Konishi M, Tanaka K, et al. Germline mutation of MSH6 as the cause of hereditary nonpolyposis colorectal cancer. Nat Genet 1997;17:271-2.
31. Wijnen J, de Leeuw W, Vasen H, et al. Familial endometrial cancer in female carriers of MSH6 germline mutations. Nat Genet 1999;23:142-4.
32. Park YJ, Shin K-H, Park J-G. Risk of gastric cancer in hereditary nonpolyposis colorectal cancer in Korea. Clin Cancer Res 2000;6:2994-8.
33. Burke C. Risk stratification for periampullary carcinoma in patients with familial adenomatous polyposis: does Theodore know what to do now? Gastroenterology 2001;121:1246-8.
34. Björk J, Akerbrant H, Iselius L, et al. Periampullary adenomas and adenocarcinomas in familial adenomatous polyposis: cumulative risks and APC gene mutations. Gastroenterology 2001;121:1127-35.
35. Lynch HT, Fitzgibbons R Jr, Chong S, et al. Use of doxorubicin and dacarbazine for the management of unresectable intraabdominal desmoid tumors in Gardner's syndrome. Dis Colon Rectum 1994;37:260-7.
36. Lynch HT, Fitzgibbons R Jr. Surgery, desmoid tumors, and familial adenomatous polyposis: case report and literature review. Am J Gastroenterol 1996;91:2598-601.
37. Lynch HT, Lynch PM. Negative genetic test result in familial adenomatous polyposis. Dis Colon Rectum 1999;42:310-2.
38. Lynch HT, Smyrk TC. Classification of familial adenomatous polyposis: a diagnostic nightmare. Am J Hum Genet 1998;62:1288-9.
39. Lynch HT, Tinley ST, Lynch J, Vanderhoof J, Lemon SJ. Familial adenomatous polyposis: discovery of a family and its management in a cancer genetics clinic. Cancer 1997;80:Suppl:614-20.
40. Lynch HT, Smyrk T, Lynch J, Lanspa S, McGinn T, Cavalieri RJ. Genetic counseling in an extended attenuated familial adenomatous polyposis kindred. Am J Gastroenterol 1996;91:455-9.
41. Lynch HT. Desmoid tumors: genotype-phenotype differences in familial adenomatous polyposis - a nosological dilemma. Am J Hum Genet 1996;59:1184-5.
42. Brensinger JD, Laken SJ, Luce MC, et al. Variable phenotype of familial adenomatous polyposis in pedigrees with 3′ mutation in the APC gene. Gut 1998;43:548-52.
43. Laken SJ, Petersen GM, Gruber SB, et al. Familial colorectal cancer in Ashkenazim due to a hypermutable tract in APC. Nat Genet 1997;17:79-83.
44. Prior TW, Chadwick RB, Papp AC, et al. The I1307K polymorphism of the APC gene in colorectal cancer. Gastroenterology 1999; 116:58-63.
45. Rozen P, Shomrat R, Strul H, et al. Prevalence of the I1307K APC gene variant in Israeli Jews of differing ethnic origin and risk for colorectal cancer. Gastroenterology 1999; 116:54-7.
46. Kinzler KW, Vogelstein B. Lessons from hereditary colon cancer. Cell 1996;87:159-70.
47. Herrera L, ed. Familial adenomatous polyposis. New York: Alan R. Liss, 1990.
48. Steinbach G, Lynch PM, Phillips RKS, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342:1946-52.
49. Tonelli F, Valanzano R, Messerini L, Ficari F. Long-term treatment with sulindac in familial adenomatous polyposis: is there an actual efficacy in prevention of rectal cancer? J Surg Oncol 2000;74:15-20.
50. Burn J, Chapman PD, Mathers J, et al. The protocol for a European double-blind trial of aspirin and resistant starch in familial adenomatous polyposis: the CAPP study. Eur J Cancer 1995;31A:1385-6.
51. Williamson SLH, Kartheuser A, Coaker J, et al. Intestinal tumorigenesis in the Apc1638N mouse treated with aspirin and resistant starch for up to 5 months. Carcinogenesis 1999;20:805-10.
52. Lynch HT, Thorson AG, Smyrk T. Rectal cancer after prolonged sulindac chemoprevention: a case report. Cancer 1995;75:936-8.
53. Aarnio M, Sankila R, Pukkala E, et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 1999;81:214-8.
54. Fusaro RM, Lemon SJ, Lynch HT. The Muir-Torre syndrome: a variant of the hereditary nonpolyposis colorectal cancer syndrome. J Tumor Marker Oncol 1996;11:19-31.
55. Lynch HT, Richardson JD, Amin M, et al. Variable gastrointestinal and urologic cancers in a Lynch syndrome II kindred. Dis Colon Rectum 1991;34:891-5.
56. Vasen HFA, Mecklin J-P, Khan PM, Lynch HT. The International Collaborative Group on Hereditary Nonpolyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum 1991;34:424-5.
57. Vasen HFA, Watson P, Mecklin J-P, Lynch HT. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative Group on HNPCC. Gastroenterology 1999;116:1453-6.
58. Smyrk TC, Watson P, Kaul K, Lynch HT. Tumor-infiltrating lymphocytes are a marker for microsatellite instability in colorectal carcinoma. Cancer 2001;91:2417-22.
59. Alexander J, Watanabe T, Wu T-T, Rashid A, Li S, Hamilton SR. Histopathological identification of colon cancer with microsatellite instability. Am J Pathol 2001;158:527-35.
60. Jass JR, Do K-A, Simms LA, et al. Morphology of sporadic colorectal cancer with DNA replication errors. Gut 1998;42:673-9.
61. Jass JR, Stewart SM. Evolution of hereditary nonpolyposis colorectal cancer. Gut 1992;33:783-6.
62. Lynch J. The genetics and natural history of hereditary colon cancer. Semin Oncol Nurs 1997;13:91-8.
63. Nyström-Lahti M, Wu Y, Moisio A-L, et al. DNA mismatch repair gene mutations in 55 kindreds with verified or putative hereditary nonpolyposis colorectal cancer. Hum Mol Genet 1996;5:763-9.
64. Wu Y, Berends MJW, Sijmons RH, et al. A role for MLH3 in hereditary nonpolyposis colorectal cancer. Nat Genet 2001;29:137-8.
65. Lindor NM, Burgart LJ, Leontovich O, et al. Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J Clin Oncol 2002;20:1043-8.
66. Yan H, Papadopoulos N, Marra G, et al. Conversion of diploidy to haploidy. Nature 2000;403:723-4.
67. Nakagawa H, Yan H, Lockman J, et al. Allele separation facilitates interpretation of potential splicing alterations and genomic rearrangements. Cancer Res 2002;62:4579-82.
68. Wijnen J, van der Klift H, Vasen H, et al. MSH2 genomic deletions are a frequent cause of HNPCC. Nat Genet 1998;20:326-8.
69. Burke W, Petersen G, Lynch P, et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. I. Hereditary nonpolyposis colon cancer. JAMA 1997;277:915-9.
70. Järvinen HJ, Aarnio M, Mustonen H, et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 2000;118:829-34.
71. Lynch HT. Is there a role for prophylactic subtotal colectomy among hereditary nonpolyposis colorectal cancer germline mutation carriers? Dis Colon Rectum 1996;39:109-10.
72. Houlston RS, Collins A, Slack J, Morton NE. Dominant genes for colorectal cancer are not rare. Ann Hum Genet 1992;56:99-103.
73. Ramsey SD, Clarke L, Etzioni R, Higashi M, Berry K, Urban N. Cost-effectiveness of microsatellite instability screening as a method for detecting hereditary nonpolyposis colorectal cancer. Ann Intern Med 2001; 135:577-88.
74. Rodriguez-Bigas MA, Boland CR, Hamilton SR, et al. A National Cancer Institute workshop on hereditary nonpolyposis colorectal cancer syndrome: meeting highlights and Bethesda guidelines. J Natl Cancer Inst 1997;89:1758-62.
75. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-67.
76. Ilyas M, Straub J, Tomlinson IPM, Bodmer WF. Genetic pathways in colorectal and other cancers. Eur J Cancer 1999;35:335-51.
77. Konishi M, Kikuchi-Yanoshita R, Tanaka K, et al. Molecular nature of colon tumors in hereditary nonpolyposis colorectal cancer, familial polyposis, and sporadic colon cancer. Gastroenterology 1996;111:307-17.
78. Huang J, Papadopoulos N, McKinley AJ, et al. APC mutations in colorectal tumors with mismatch repair deficiency. Proc Natl Acad Sci U S A 1996;93:9049-54.
79. Duval A, Rolland S, Compoint A, et al. Evolution of instability at coding and noncoding repeat sequences in human MSI-H colorectal cancers. Hum Mol Genet 2001; 10:513-8.
80. Chadwick RB, Jiang G-L, Bennington GA, et al. Candidate tumor suppressor RIZ is frequently involved in colorectal carcinogenesis. Proc Natl Acad Sci U S A 2000;97:2662-7.
81. Chadwick RB, Pyatt RE, Niemann TH, et al. Hereditary and somatic DNA mismatch repair gene mutations in sporadic endometrial carcinoma. J Med Genet 2001;38:461-6.
82. Malkhosyan S, Rampino N, Yamamoto H, Perucho M. Frameshift mutator mutations. Nature 1996;382:499-500.
83. Kane MF, Loda M, Gaida GM, et al. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res 1997;57:808-11.
84. Herman JG, Umar A, Polyak K, et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A 1998;95:6870-5.
85. Cunningham JM, Christensen ER, Tester DJ, et al. Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. Cancer Res 1998;58:3455-60.
86. Veigl ML, Kasturi L, Olechnowicz J, et al. Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers. Proc Natl Acad Sci U S A 1998;95:8698-702.
87. Nakagawa H, Chadwick RB, Peltomäki P, Plass C, Nakamura Y, de la Chapelle A. Loss of imprinting of the insulin-like growth factor II gene occurs by biallelic methylation in a core region of H19-associated CTCF-binding sites in colorectal cancer. Proc Natl Acad Sci U S A 2001;98:591-6.
88. Hemminki A, Markie D, Tomlinson I, et al. A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature 1998;391:184-7.
89. Howe JR, Roth S, Ringold JC, et al. Mutations in the SMAD4/DPC4 gene in juvenile polyposis. Science 1998;280:1086-8.
90. Howe JR, Bair JL, Sayed MG, et al. Germline mutations of the gene encoding bone morphogenetic protein receptor 1A in juvenile polyposis. Nat Genet 2001;28:184-7.
91. Lynch ED, Ostermeyer EA, Lee MK, et al. Inherited mutations in PTEN that are associated with breast cancer, Cowden disease, and juvenile polyposis. Am J Hum Genet 1997; 61:1254-60.
92. Liaw D, Marsh DJ, Li J, et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 1997;16:64-7.
93. Marsh DJ, Coulon V, Lunetta KL, et al. Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. Hum Mol Genet 1998;7:507-15.
94. Eng C, Ji H. Molecular classification of the inherited hamartoma polyposis syndromes: clearing the muddied waters. Am J Hum Genet 1998;62:1020-2.
95. Matloff ET, Shappell H, Brierley K, Bernhardt BA, McKinnon W, Peshkin BN. What would you do? Specialists' perspectives on cancer genetic testing, prophylactic surgery, and insurance discrimination. J Clin Oncol 2000;18:2484-92.
96. Pokorski RJ, Sanderson P, Bennett N, et al. Insurance issues and genetic testing: challenges and recommendations: workshop no. 1. Cancer 1997;80:Suppl:627.
97. The Ad Hoc Committee on Genetic Testing/Insurance Issues. Genetic testing and insurance. Am J Hum Genet 1995;56:327-31.
98. Balanced Budget Act of 1997, Pub. L. No. 105-33, 105th Cong. 1st Sess.
99. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344: 1031-7.
100. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344:1038- 42. [Erratum, N Engl J Med 2001;345:232.]
101. Al-Tassan N, Chmiel NH, Maynard J, et al. Inherited variants of MYH associated with somatic G:C→T:A mutations in colorectal tumors. Nat Genet 2002;30:227-32.
102. Sieber OM, Lipton L, Crabtree M, et al. Multiple colorectal adenomas, classic adenomatous polyposis, and germ-line mutations in MYH. N Engl J Med 2003;348:791-9.